MX2017003237A - Metodo para producir esteres de astaxantina. - Google Patents

Metodo para producir esteres de astaxantina.

Info

Publication number
MX2017003237A
MX2017003237A MX2017003237A MX2017003237A MX2017003237A MX 2017003237 A MX2017003237 A MX 2017003237A MX 2017003237 A MX2017003237 A MX 2017003237A MX 2017003237 A MX2017003237 A MX 2017003237A MX 2017003237 A MX2017003237 A MX 2017003237A
Authority
MX
Mexico
Prior art keywords
formula
diester
therapeutic use
general formula
producing astaxanthin
Prior art date
Application number
MX2017003237A
Other languages
English (en)
Inventor
Siegel Wolfgang
Schäfeer Bernd
BENSON Stefan
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of MX2017003237A publication Critical patent/MX2017003237A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a un método ecológico, económico y que conserva los recursos para producir ésteres de astaxantina de la Fórmula 1, en donde la astaxantina de la Fórmula 2 se esterifica doblemente con cloruros de ácidos grasos de la Fórmula general 3. Para este propósito, los compuestos 2 y 3 se hacen reaccionar en un solvente orgánico en presencia de una base que contiene nitrógeno de la Fórmula general 4. La invención también se refiere al uso no terapéutico del diéster 1, en donde R representa un residuo que se selecciona del grupo que consiste en C13 - C19 alquilo, C13 - C19 alquenilo, C13 - C19 alkdienilo y C13 - C19 alktrienilo, en la nutrición de seres humanos o animales, y al diéster 1 producido de acuerdo con el método, para el uso terapéutico como un medicamento y como un ingrediente para una preparación médica.
MX2017003237A 2014-09-11 2015-08-11 Metodo para producir esteres de astaxantina. MX2017003237A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184483 2014-09-11
PCT/EP2015/068445 WO2016037785A1 (de) 2014-09-11 2015-08-11 Verfahren zur herstellung von astaxanthinestern

Publications (1)

Publication Number Publication Date
MX2017003237A true MX2017003237A (es) 2017-06-29

Family

ID=51542186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003237A MX2017003237A (es) 2014-09-11 2015-08-11 Metodo para producir esteres de astaxantina.

Country Status (11)

Country Link
US (1) US20170305849A1 (es)
EP (1) EP3191448A1 (es)
JP (1) JP2017526712A (es)
KR (1) KR20170052630A (es)
CN (1) CN106687443A (es)
AU (1) AU2015314580A1 (es)
BR (1) BR112017004761A2 (es)
CA (1) CA2958386A1 (es)
MX (1) MX2017003237A (es)
RU (1) RU2017112051A (es)
WO (1) WO2016037785A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2693455C2 (ru) 2014-05-20 2019-07-03 Аста Фармасьютикалз Ко., Лтд. Каротеноидное производное, его фармацевтически приемлемая соль и фармацевтическая композиция, содержащая его
EP3274465B1 (de) 2015-03-26 2022-08-03 Basf Se Biokatalytische herstellung von l-fucose
DK3294700T3 (da) 2015-05-08 2020-04-14 Basf Agro Bv Fremgangsmåde til fremstilling af limonen-4-ol
EP3294720B1 (en) 2015-05-08 2020-12-02 BASF Agro B.V. A process for the preparation of terpinolene epoxide
PL3319951T3 (pl) 2015-07-10 2022-02-28 Basf Se Sposób hydroformylowania 2-podstawionych butadienów oraz wytwarzania ich produktów pochodnych, w szczególności ambroksu
MX380770B (es) 2016-02-19 2025-03-12 Basf Se Ciclación enzimática de ácido homofarnesílico.
ES2833202T3 (es) 2016-06-15 2021-06-14 Basf Agro Bv Procedimiento para la epoxidación de un alqueno tetrasustituido
EP3472139B1 (en) 2016-06-15 2021-04-07 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
CN108250119A (zh) * 2018-03-07 2018-07-06 广州立达尔生物科技股份有限公司 从侧金盏花油树脂中提纯制备高含量天然虾青素酯的方法
WO2022140580A1 (en) 2020-12-24 2022-06-30 Orn Almarsson Xanthophyll derivatives
KR102885420B1 (ko) 2022-09-07 2025-11-13 전북대학교산학협력단 크립토캅신과 루테인을 주성분으로 하는 복합 추출물 및 그의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07300421A (ja) * 1994-04-28 1995-11-14 Itano Reitou Kk 抗炎症剤
DE10049271A1 (de) 2000-09-28 2002-04-11 Basf Ag Verfahren zur katalytischen Reduktion von Alkinverbindungen
DE10140180A1 (de) 2001-08-22 2003-03-06 Basf Ag Verfahren zur selektiven Reduktion von Alkinverbindungen
MX247604B (es) * 2002-02-06 2007-07-30 Dsm Ip Assets Bv Esteres de astaxantina.
ES2223270B1 (es) 2003-04-10 2006-04-16 Carotenoid Technologies, S.A. Procedimiento para la sintesis de astaxantina.
CN101386879A (zh) * 2008-10-30 2009-03-18 广州立达尔生物科技有限公司 一种制备虾青素酯的方法
TWI501946B (zh) 2010-02-08 2015-10-01 Basf Se 蝦紅素二琥珀酸二甲酯之製造方法

Also Published As

Publication number Publication date
RU2017112051A (ru) 2018-10-11
AU2015314580A1 (en) 2017-04-06
US20170305849A1 (en) 2017-10-26
WO2016037785A1 (de) 2016-03-17
KR20170052630A (ko) 2017-05-12
EP3191448A1 (de) 2017-07-19
BR112017004761A2 (pt) 2017-12-05
CN106687443A (zh) 2017-05-17
RU2017112051A3 (es) 2019-03-06
JP2017526712A (ja) 2017-09-14
CA2958386A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
MX2017003237A (es) Metodo para producir esteres de astaxantina.
MY188027A (en) Fat composition and fat blend
CL2017000071A1 (es) Acidos carboxílicos hterocíclicos como activadores de guanilato ciclasa soluble.
PH12017502331A1 (en) 1,4-substituted piperidine derivatives
MY210123A (en) Tlr7/8 antagonists and uses thereof
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
TN2017000031A1 (en) Imidazopyridazine compounds
MX348960B (es) Uso de composiciones grasas para mantener una palatabilidad mejorada de alimentos para animales domesticos en el tiempo.
PH12019501362B1 (en) Polymorphs
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
PE20181040A1 (es) Formulacion solida oral que contiene irinotecan y metodo de preparacion de la misma
EP3177755A4 (en) High productivity kolbe reaction process for transformation of fatty acids derived from plant oil and animal fat
MX386294B (es) Esteres de oxaborol y sus usos
IL246254B (en) Compounds of omega-3 fatty acids for the treatment of diseases involving damage to the nervous system
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
JOP20200155A1 (ar) صور متعددة الأشكال
MX378591B (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico
MX392586B (es) Derivados de la espiropiperidina.
EP2935170A4 (en) HYDROGENATION PRODUCTS FROM BIOLOGICALLY DERIVED CARBOXYLIC ACID ESTERS
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).